SCHOTT AG, a German high-tech specialty glass group, and Schott Xinkang, a joint venture established by Zhejiang Xinkang Pharmaceutical Glass Co., Ltd., opened a new plant in Jinyun, Zhejiang. The first phase of the project will have a total investment of 400 million yuan and will be officially put into operation on October 18, 2017. At that time, SCHOTT Xinkang will become the top glass packaging supplier for injection quality in China's production quality and production capacity, with an annual production capacity of 2 billion, and produce the highest quality drugs for the Chinese pharmaceutical market through automated production lines and advanced visual inspection systems. Packaging products. Zhejiang Jinyun--September 27, 2017 -- Schott Xinkang is a joint venture established by German high-tech group SCHOTT AG and Zhejiang Xinkang Pharmaceutical Glass Co., Ltd., its new special glass in Jinyun, Zhejiang. The pharmaceutical packaging production base will be officially put into operation on October 18, 2017. The plant will produce ampoules, vials, cartridges and other pharmaceutical packaging for injectables using high quality glass tubes. SCHOTT Xinkang aims to provide the highest quality pharmaceutical packaging for the Chinese market in accordance with international standards, and the new plant will become an important new link for the global supply chain of SCHOTT Medical Systems, which already includes Russia, Brazil and India. . After the expansion of the new plant, SCHOTT China's production capacity is expected to increase by 50%. Top supplier in the Chinese market In the past decade, China has invested huge capital in construction projects with high quality requirements and short turnaround times, which has stimulated the confidence of foreign investors. As a German high-tech company known for its rich technology and industrial R&D history, SCHOTT believes that China has the ability to build factories in accordance with strict international standards. Coupled with the rapid development of China's pharmaceutical packaging market, this prompted Schott to establish a joint venture with Zhejiang Xinkang Pharmaceutical Glass Co., Ltd. The first phase of the project has a total investment of 51 million euros (about 400 million yuan). The new plant will produce high quality glass primary packaging products in various specifications. In the first phase of operation, the plant has an annual production capacity of 2 billion. With this in mind, SCHOTT Xinkang is a leader in production quality, capacity and plant design and construction. In response to the demand in the Chinese market, Andreas Reisse, Executive Vice President of SCHOTT Medical Systems commented: “When imports are insufficient to meet the growing demand in the Chinese pharmaceutical market, SCHOTT Xinkang has to continue to expand its product range and respond quickly to demand and market. Change and improve service. Our investment and future plans show that SCHOTT values ​​China's important market." Setting standards for the highest quality pharmaceutical packaging In order to achieve the highest quality, the design and construction of the new plant are among the top levels in the Chinese pharmaceutical packaging industry. SCHOTT Xinkang will use a highly automated vial and ampoule production line and monitor it with a visual inspection system. “To ensure global quality, all SCHOTT Group equipment, such as cameras and automatic inspection systems, need to achieve uniform high precision and high standards. By using quality raw materials and applying our expertise in the glass industry, we The production not only meets or exceeds the ever-increasing industry standards of regulators and the pharmaceutical industry," said Chen Guangxin, managing director of SCHOTT Xinkang. All products are manufactured and packaged in a controlled environment that is ISO 9001 and 15378 certified and complies with the European Pharmacopoeia (Ph. Eur), the United States Pharmacopoeia (USP) and the Japanese Pharmacopoeia (JP). ) International standards. SCHOTT Xinkang hopes that adhering to high standards and best practices can play an important role in promoting the development of China's pharmaceutical industry. In addition to its impact on the industry, SCHOTT Xinkang has also worked closely with government agencies and community people to make an important contribution to the local economy. Temporary Flood Boxwalls,Temporary Flood Barrier,Quick Flood Barrier,Flood Barrier Door Denilco Environmental technology(Suzhou)Co., Ltd. , https://www.wflood.com